Ibrutinib Versus Temsirolimus: 3-Year Follow-Up of Patients With Previously Treated Mantle Cell Lymphoma From the Phase 3, International, Randomized, Open-Label RAY Study
Leukemia - United Kingdom
doi 10.1038/s41375-018-0023-2
Full Text
Open PDFAbstract
Available in full text
Date
February 2, 2018
Authors
Publisher
Springer Science and Business Media LLC